Erlotinib vs etoposide/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: A multicenter, randomized, open-label, phase 2 trial.
机构:[1]Department of Radiation Oncology and Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China[2]Cancer Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[3]Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China[4]Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Clinical College of Fujian Medical University, Fuzhou, China[5]Department of Radiation Oncology, Zhengzhou University Cancer Hospital, Zhengzhou, China[6]Department of Radiation Oncology, CyberKnife Center, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China[7]Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[8]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[9]Department of Thoracic Oncology, Huaxi Hospital, Sichuan University, Chengdu, China四川大学华西医院[10]Department of Thoracic Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[11]Department of Radiation Oncology, Air Force General Hospital, Beijing, China[12]Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China[13]Department of Radiation Oncology, First Hospital of China Medical University, Shenyang, China[14]Department of Oncology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China[15]Department of Radiation Oncology, Guizhou Cancer Hospital, Guiyang, China[16]Department of Radiation Oncology, First Affiliated Hospital of Xiamen University, Xiamen, China[17]Department of Radiation Oncology, Beijing Cancer Hospital, Beijing, China[18]Department of Radiation Oncology, PLA General Hospital, Beijing, China[19]Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.[20]Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai, China.[21]Department of Radiation Oncology, China-Japan Friendship Hospital, Beijing, China.
This work was funded by Shanghai Roche Pharmaceuticals Ltd, the
National Key Research and Development Projects of China
(2016YFC0904700) and the Key Research and Development Program of
Shandong Province (2016CYJS01A03).
语种:
外文
被引次数:
WOS:
PubmedID:
JCR分区:
出版当年[2021]版:
Q1ONCOLOGYQ1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
最新[2024]版:
Q1ONCOLOGYQ1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
第一作者机构:[1]Department of Radiation Oncology and Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China
通讯作者:
推荐引用方式(GB/T 7714):
Ligang Xing,Gang Wu,Luhua Wang,et al.Erlotinib vs etoposide/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: A multicenter, randomized, open-label, phase 2 trial.[J].International Journal Of Radiation Oncology, Biology, Physics.2021,109(5):1349-1358.doi:10.1016/j.ijrobp.2020.11.026.
APA:
Ligang Xing,Gang Wu,Luhua Wang,Jiancheng Li,Jianhua Wang...&Jinming Yu.(2021).Erlotinib vs etoposide/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: A multicenter, randomized, open-label, phase 2 trial..International Journal Of Radiation Oncology, Biology, Physics,109,(5)
MLA:
Ligang Xing,et al."Erlotinib vs etoposide/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: A multicenter, randomized, open-label, phase 2 trial.".International Journal Of Radiation Oncology, Biology, Physics 109..5(2021):1349-1358